PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.42%
Revenue growth 1.25-1.5x 3088.T's 8.93%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
8.17%
Gross profit growth above 1.5x 3088.T's 4.84%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-1.82%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
18.93%
Operating income growth under 50% of 3088.T's 114.85%. Michael Burry would be concerned about deeper cost or sales issues.
1.60%
Positive net income growth while 3088.T is negative. John Neff might see a big relative performance advantage.
1.65%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
1.65%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
99.82%
Dividend growth under 50% of 3088.T's 7650.00%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
-52.95%
Negative OCF growth while 3088.T is at 152.07%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-67.96%
Negative FCF growth while 3088.T is at 121.24%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
15.33%
10Y revenue/share CAGR above 1.5x 3088.T's 7.03%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
15.33%
5Y revenue/share CAGR above 1.5x 3088.T's 7.03%. David Dodd would look for consistent product or market expansions fueling outperformance.
15.33%
3Y revenue/share CAGR above 1.5x 3088.T's 7.03%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
129.00%
10Y OCF/share CAGR above 1.5x 3088.T's 56.05%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
129.00%
5Y OCF/share CAGR above 1.5x 3088.T's 56.05%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
129.00%
3Y OCF/share CAGR above 1.5x 3088.T's 56.05%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
8.12%
Positive 10Y CAGR while 3088.T is negative. John Neff might see a substantial advantage in bottom-line trajectory.
8.12%
Positive 5Y CAGR while 3088.T is negative. John Neff might view this as a strong mid-term relative advantage.
8.12%
Positive short-term CAGR while 3088.T is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.20%
10Y dividend/share CAGR above 1.5x 3088.T's 0.65%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
53.20%
5Y dividend/share CAGR above 1.5x 3088.T's 0.65%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
53.20%
3Y dividend/share CAGR above 1.5x 3088.T's 0.65%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
No Data
No Data available this quarter, please select a different quarter.
-4.73%
Inventory is declining while 3088.T stands at 1.96%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
2.98%
Asset growth at 75-90% of 3088.T's 3.78%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
4.13%
Positive BV/share change while 3088.T is negative. John Neff sees a clear edge over a competitor losing equity.
-24.33%
We’re deleveraging while 3088.T stands at 12.70%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.